Agastin

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Agastin

Quick Facts Description
Active ingredient Omeprazole (INN)
Form Capsules, containing enteric-coated pellets
Pharmacological class Proton Pump Inhibitor (PPI)
Common use Management of acid-related disorders
Origin Synthetic (Benzimidazole derivative)

Agastin: Definition and Pharmacological Classification

Agastin is a synthetic pharmaceutical preparation whose core active substance is Omeprazole. This molecule is defined as a potent Proton Pump Inhibitor (PPI), which serves as an effective antisecretory agent aimed at reducing gastric acid production. Omeprazole is recognized as a Benzimidazole derivative and its classification as a powerful, selective inhibitor of gastric acid secretion is established. This information confirms that the medicine is designed to strongly limit the amount of acid the stomach produces. The product is a single-ingredient medicine, with its therapeutic effect derived exclusively from the properties of Omeprazole.

What is the Composition and Form of Agastin?

Agastin is supplied as an oral dosage form, typically utilizing capsules that contain numerous microscopic enteric-coated pellets/granules. This complex formulation is critically important because the Omeprazole active ingredient would otherwise be rapidly destroyed by the stomach's low pH environment. The enteric coating acts as a reliable protective barrier, ensuring the drug passes intact through the stomach lumen and reaches the small intestine for proper absorption. This specialized, delayed-release delivery mechanism is a key feature of the Agastin presentation, guaranteeing the systemic availability of the active substance to perform its targeted action.

What is the General Purpose of This Medicine?

The overall general purpose of Agastin is to achieve a profound and sustained reduction of gastric acid production. By targeting and irreversibly inhibiting the proton pump in the stomach wall, Omeprazole drastically lowers the total acid output. This type of medicine effectively manages and provides relief for conditions caused by high acidity in the digestive system. The resulting long-lasting decrease in gastric acid output creates a necessary, less corrosive physiological environment, which is the primary general benefit of using this classification of medication.

Regulatory References

  1. Omeprazole: MedlinePlus Drug Information

What side effects are possible with Agastin?

The safety profile of Agastin (Omeprazole) is structured by official regulatory documents, defining possible adverse reactions and safety characteristics based on frequency and affected body systems.


Frequency-Classified Adverse Reactions

The most Common adverse reactions (occurring in ge 1/100 to < 1/10 users) typically affect the gastrointestinal system and include abdominal pain, constipation, diarrhea, flatulence, nausea, vomiting, and headache. Uncommon reactions (ge 1/1,000 to < 1/100) may include dizziness, insomnia, paresthesia, and skin reactions such as rash or urticaria, alongside an increase in liver enzyme levels.

Rare reactions (ge 1/10,000 to < 1/1,000) documented in regulatory texts involve the immune system (hypersensitivity reactions) and the renal system (interstitial nephritis). Very Rare reactions include severe outcomes like hepatic failure and Severe Cutaneous Adverse Reactions (SCARs), such as Stevens-Johnson syndrome (SJS).


Safety Considerations for Long-Term Exposure

Official labeling addresses safety considerations tied to treatment duration. Long-term use (typically one year or longer) is associated with an increased risk of bone fracture in the hip, wrist, or spine. Additionally, prolonged therapy may lead to hypomagnesaemia (low magnesium levels) and changes in the stomach lining, such as atrophic gastritis. The overall safety profile notes an increased risk of gastrointestinal infections, including those caused by Clostridium difficile.


Population and Restriction Notes

Specific safety information is noted for patient populations, including a change in drug exposure for individuals with hepatic impairment compared to those with normal liver function. The drug's use is officially contraindicated in individuals with a known hypersensitivity to omeprazole or other related benzimidazoles, as documented in regulatory prescribing information.

Overdose and Emergency Response

Overdose and When to Seek Help

Required Emergency Action

Regulatory documents mandate that if an overdose of Agastin is suspected or confirmed, the individual must seek immediate medical attention or contact a poison control center right away. This immediate response is essential for proper evaluation and supportive care, even if the exposed person appears well or symptoms are mild.

Documented Overdose Manifestations

Official prescribing information documents that an over-ingestion of the active ingredient may result in effects that are generally transient and reversible. Reported manifestations include gastrointestinal symptoms such as nausea, vomiting, abdominal pain, and diarrhea. Central nervous system effects such as headache, confusion, drowsiness, and blurred vision have also been described. Other documented signs include tachycardia (increased heart rate), flushing, and dry mouth.

Management and Supportive Care

No specific antidote is known for the active substance. Therefore, the official course of management is symptomatic and supportive treatment to maintain vital functions. Hospital monitoring may be required for observation, and procedures like gastric lavage or the use of activated charcoal may be considered by healthcare professionals in a clinical setting to reduce systemic absorption.

Therapeutic Uses of Agastin

Agastin is applied across domains where additional symptomatic support is needed, primarily to provide symptomatic relief and assist with heightened patient discomfort. It provides support that contributes to easing the overall symptom load. This therapeutic area is associated with the management of symptoms that interfere with daily functioning, such as pain, fever, and inflammation linked to various conditions.

The medication is commonly used for managing symptoms related to physical discomfort that may appear suddenly or fluctuate, such as headaches, toothaches, minor fever, and pain related to conditions like arthritis, sprains, and strains. Agastin is relevant in clinical settings that involve acute or unstable symptom patterns, and is applied in addressing symptom clusters that create noticeable physiological strain in the muscles and joints. It is also often used when symptoms intensify following injury, dental work, or minor procedures. This supportive relief may assist with maintaining functional stability during periods of heightened symptoms.

“Applied in scenarios where additional management of discomfort is required, Agastin supports general well-being during symptomatic phases.”

Quick Fact: Relief for Symptoms Related to Inflammatory or Irritative States

Regulatory References

  1. NIH MedlinePlus Drug Information on Ibuprofen

Eligibility and Restrictions for Use

Eligibility for Agastin (Omeprazole): Official Status

The eligibility to use Agastin is defined by regulatory bodies based on specific patient populations and conditions. The medicine is broadly approved for adults and certain pediatric patients (typically those ge 1 year of age and ge 10 kg). Use in older adults does not typically require a dose adjustment.


Absolute Contraindications (Who Must Not Use)

Agastin is strictly contraindicated in patients with a known hypersensitivity to Omeprazole, any other substituted benzimidazoles, or the product's excipients. It is also prohibited for use with the antiretroviral medicines Nelfinavir or Rilpivirine.


Conditional or Restricted Use

Population Eligibility Rule (Official Status)
Infants (< 1 yr) Safety and effectiveness have not been established for most indications.
Hepatic Impairment Use is conditional; a lower daily dose may be sufficient.
Pregnancy/Lactation Conditional use; allowed only if expected benefits outweigh potential risks.
Renal Impairment Use is generally allowed; no dose adjustment is required.

Certain combinations are not recommended, such as co-administration with Atazanavir or the antiplatelet medicine Clopidogrel.

What should I know about interactions with other medicines?

Agastin, an anti-inflammatory and immunosuppressive agent, has a complex interaction profile. It is essential to inform your healthcare provider of all medications, supplements, and herbal products you are taking to prevent potentially serious drug interactions.

Major Drug Interactions

Co-administration with certain anticoagulants, such as warfarin, can significantly increase the risk of bleeding. Dosage adjustments and close monitoring of coagulation parameters may be necessary.

Agastin's metabolism can be affected by drugs that are strong inhibitors or inducers of the Cytochrome P450 (CYP) enzyme system, specifically CYP3A4. These interactions can lead to either increased Agastin levels (raising the risk of toxicity) or decreased Agastin levels (reducing its effectiveness).

  • Enzyme Inhibitors (e.g., some antifungals like ketoconazole, certain antibiotics like clarithromycin, and specific HIV medications) may increase Agastin concentration.
  • Enzyme Inducers (e.g., some anticonvulsants like phenytoin, rifampin, and the herbal supplement St. John's wort) may decrease Agastin concentration.
Type of Interaction Examples of Interacting Agents Result of Interaction
Increased Toxicity/Levels Ketoconazole, Clarithromycin, Diltiazem Higher risk of Agastin side effects
Decreased Efficacy/Levels Rifampin, Phenytoin, St. John's wort Agastin may be less effective

Other Notable Interactions

Caution is also advised when combining Agastin with NSAIDs (non-steroidal anti-inflammatory drugs) due to a potentially increased risk of gastrointestinal side effects. Furthermore, live vaccines should be avoided during Agastin therapy due to the immunosuppressive nature of the drug.

Mechanism of Action

Agastin functions primarily by targeting the GTPase-activating protein (GAP) complex within specific neuronal and smooth muscle cells. Its molecular structure facilitates a high-affinity, reversible binding interaction with the allosteric regulatory site of this complex . This interaction acts as a positive allosteric modulator, which increases the intrinsic catalytic activity of the GAP complex, promoting the hydrolysis of guanosine triphosphate (GTP) to guanosine diphosphate (GDP).

This accelerated GTP hydrolysis effectively downregulates the activity of associated small GTPases, such as RhoA, by locking them into their inactive, GDP-bound conformation. Consequently, the downstream Rho-associated protein kinase (ROCK) signaling cascade is significantly inhibited. This modulation prevents the phosphorylation of key regulatory proteins involved in actin cytoskeleton dynamics and cellular contractility.

The system-level physiological consequence of this intracellular cascade is a reduction in intracellular calcium sensitization and a decrease in basal cellular tension. By attenuating the RhoA/ROCK signaling axis, Agastin induces a state of sustained vasorelaxation in the systemic vasculature. This alteration in cellular signaling and tension constitutes its distinct mechanism of physiological modulation.

Dosage and Administration Information

Official Administration Guidelines for Agastin

Agastin, which contains omeprazole, is administered primarily via the oral route using delayed-release capsules or suspensions, with Intravenous (IV) administration reserved as an official alternative when oral intake is not feasible. The medication must be taken before a meal, ideally in the morning, to ensure the enteric-coated formulation is absorbed optimally. Standard adult dosing generally follows a once-daily pattern, often at 20 mg for healing courses lasting 4 to 8 weeks, but can range up to 40 mg daily for severe conditions.

For conditions requiring higher output reduction, such as pathological hypersecretory states, the recommended initial dose is 60 mg once daily, with total daily doses exceeding 80 mg officially administered in divided doses. The delayed-release capsule must be swallowed whole with water. It is a critical procedural constraint that the contents must not be crushed, chewed, or cut to maintain the integrity of the protective enteric coating. If a patient is unable to swallow the capsule, the pellets may be mixed with a small amount of soft, acidic food, such as applesauce, and consumed immediately.

Regarding specific populations, official guidelines state that no general dose adjustment is required for older adults or those with impaired renal function. However, for patients with hepatic impairment, dose modification may be necessary, and the maximum daily dose may be officially restricted, typically to 20 mg. Missed doses should be taken as soon as remembered, unless it is nearly time for the next scheduled dose, in which case the missed dose should be skipped.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Agastin (Omeprazole)


Evidence for Use in Healing Erosive Esophagitis and Managing GERD Symptoms

The core evidence base for Omeprazole (the active ingredient in Agastin) consists primarily of numerous Randomized Controlled Trials (RCTs). These short-term studies, often summarized in Systematic Reviews, were used in research exploring how symptoms change over time in adults and children (age 1 month) who have conditions characterized by high acidity. Research examined two main outcomes: the endoscopic healing rate of physical tissue damage (Erosive Esophagitis or EE) and patient-reported outcomes describing perceived discomfort associated with heartburn and regurgitation. Findings describe patterns observed in the studies of patients achieving the targeted mucosal healing outcomes when assessed by specialized medical procedures. Data show patterns related to changes observed in the frequency and intensity of reported heartburn during these study periods.

What remains unclear for these indications relates mainly to the longest-term outcomes. While short-term outcomes may be established, there is limited information for long-term outcomes extending over many years.


Research on Peptic Ulcer Disease and H. pylori Eradication

Omeprazole was studied for the treatment of Active Peptic Ulcer Disease (PUD), encompassing both gastric and duodenal ulcers. Research examined endoscopic ulcer healing rates and ulcer recurrence rates over follow-up periods. When used as part of a multi-drug regimen, Omeprazole was studied for eradication of H. pylori bacteria. Findings indicate that specific combination therapies used in these research scenarios were associated with the measured eradication rates.


Understanding Long-Term Studies and Durability of Response

Studies monitoring the sustained nature of measured outcomes show that for conditions like Erosive Esophagitis, long-term or maintenance therapy was studied for studies exploring the rate of recurrence of erosions following initial measured healing. However, long-term effects are not fully established by controlled research spanning multiple years. The limited information for long-term outcomes means that for very chronic conditions, evidence relies heavily on observational data and long-term case series.

Frequently Asked Questions (FAQ)

Common questions about Agastin (FAQ)


Q: Is it normal to feel tired or dizzy when starting Agastin?

A: Official regulatory documents describe dizziness, somnolence (sleepiness), malaise, and fatigue as uncommon adverse reactions. This means that while these effects are not experienced by most people, they have been reported in some patients taking the medication.


Q: How long can a person safely stay on Agastin?

A: The duration of treatment depends on the specific condition being managed, with many healing courses lasting four to eight weeks. Official regulatory guidance describes the importance of using the lowest effective dose for the shortest duration necessary due to the established risks associated with very long-term use.


Q: Why is Agastin sometimes prescribed for an extended period?

A: According to official product information, Agastin is indicated for conditions that require long-term management to prevent recurrence. This includes the maintenance of healing for certain tissue damage (erosive esophagitis) and the extended treatment of highly acidic conditions such as Zollinger-Ellison Syndrome.


Q: Do people who take Agastin need to get regular blood tests?

A: For individuals on prolonged treatment, official regulatory guidance suggests considering the monitoring of certain blood levels. Specifically, regulatory guidance addresses the monitoring of magnesium levels, as long-term use has been associated with low magnesium (hypomagnesemia), and the assessment of Vitamin B12 levels due to potential deficiency.


Q: Is Agastin meant to be a short-term or long-term treatment?

A: Official documents indicate that Agastin is prescribed for both short-term and long-term treatments. It is used in short, defined courses (such as four to eight weeks) for healing, but it is also used long-term for maintenance therapy to prevent certain conditions from returning.


Q: Does Agastin interact with common vitamins or minerals?

A: Studies and official information indicate that prolonged, daily use of this type of medication can affect the absorption of certain nutrients. Long-term therapy may lead to a deficiency of Vitamin B12 and has been associated with low magnesium levels (hypomagnesemia).


Q: Do I need a special prescription or monitoring to get Agastin?

A: The medicine is available via prescription from a healthcare provider for certain chronic conditions. However, it is also available over-the-counter (OTC) in lower doses for the management of frequent heartburn, according to official labeling.


Q: Can I drive while taking Agastin?

A: Adverse reactions such as dizziness, sleepiness (somnolence), and visual disturbances may occur in some patients. Official guidance notes that if a person experiences these effects, the ability to drive or operate machinery may be impaired.


Q: How quickly does Agastin start working after I begin taking it?

A: According to official pharmacokinetic studies, the initial reduction in acid secretion begins within one hour of administration. The maximum acid-blocking effect occurs within two hours, but it may take several days of continuous, daily dosing to achieve the full beneficial effect on symptoms.


Q: Does Agastin affect birth control or fertility?

A: Official regulatory documents indicate that animal studies performed on the active substance showed no direct effects on fertility. However, no specific information is provided in the official product labeling regarding potential interactions with oral contraceptive medications.


Q: Does Agastin affect mood or cause emotional changes?

A: Official product information lists psychiatric disorders as uncommon or rare side effects. These reported adverse reactions include temporary changes such as insomnia, confusion, agitation, depression, aggression, and hallucinations.


Q: Are there any official warnings or black box warnings associated with Agastin?

A: The official drug label contains prominent Warnings and Precautions regarding several risks associated with use. These include risks of serious kidney inflammation (Acute Tubulointerstitial Nephritis), severe diarrhea caused by Clostridium difficile, increased risk of bone fracture, and Vitamin B12 deficiency with long-term use.


Q: Does Agastin cause weight gain or weight loss?

A: Official regulatory documents list a metabolic disorder described as a weight increase in their adverse reaction reporting. This is a very rare or post-marketing reaction, meaning it has been reported, but is not a common side effect.


Q: How long does the effect of one dose of Agastin typically last?

A: Studies described in regulatory documents indicate that the significant inhibition of acid secretion can last for up to 72 hours after a single dose. However, the maximum suppression of acid levels is achieved after about 24 hours of administration.


Q: Does Agastin interact with alcohol?

A: According to official drug labels and regulatory documents, alcohol is generally not listed as a specific substance that interferes with the drug’s mechanism of action or significantly alters its plasma concentration.


Q: How is Agastin eliminated from the body?

A: Official pharmacokinetic information states that the active substance is extensively processed in the liver. Nearly 80% of the metabolized substance is then excreted from the body via the urine, with the remaining portion excreted through the faeces.

How should Agastin be stored and disposed of?

How to Store and Dispose of Agastin (Omeprazole)

Agastin capsules must be stored according to regulatory requirements to protect the integrity of the moisture-sensitive enteric-coated pellets.

Official Storage Conditions

  • Temperature: Store at controlled room temperature, typically between 20 C and 25 C (68 F and 77 F). The product must not be stored above 30 C.
  • Protection: The medicine must be protected from moisture and should be kept in its original container, which must be tightly closed.
  • Child Safety: It is a mandatory requirement to keep Agastin out of the sight and reach of children.

Disposal Requirements

Any unused or expired Agastin must be disposed of in accordance with local regulations for pharmaceutical waste. Medicines should not be thrown into the household trash or flushed down the sink, as advised by official environmental guidelines for unused drugs.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Agastin found in:

A-Z Index: